GSK remains resilient on tariffs as Q1 sales rise 4%
GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it …
Post
-
-
Novartis to strengthen renal disease portfolio with Regulus
Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal disease offerings. The upfront cash …
-
FDA approves J&J’s Imaavy for generalised myasthenia gravis
Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has received US Food and Drug Administration …
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US …
-
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led …
-
Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution
Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025, with $6.5bn raised—a 20.2% decline from the $8.1bn raised …
-
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with …
-
Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing …
-
Donald Trump’s first 100 days: Impact on the healthcare industry
When Donald Trump descended a golden escalator at Trump Tower in New York City in 2015 to announce the launch …
-
Magazine: The GLP-1 shortage is over. What’s next for compounders?
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to …
-
FDA approves AbbVie’s upadacitinib for giant cell arteritis
The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant …
-
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona Therapeutics has secured US Food and Drug Administration (FDA) approval for Zevaskyn (prademagene zamikeracel), a gene-corrected cell therapy designed …
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to …
-
Impending US tariffs signal uncertain future for global pharma, says GlobalData
In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised …
-
Construction begins on MSD’s $1bn biologics centre in Delaware, US
Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US. The …
